期刊文献+

2009-2011年杭州地区甲型H1N1流感病毒神经氨酸酶基因的遗传进化分析 被引量:3

Genetic evolution of the novel influenza A(H1N1) virus neuraminidase in Hangzhou,Zhejiang
原文传递
导出
摘要 目的了解2009年7月以来杭州地区甲型H1N1流感病毒神经氨酸酶基因(NA)的变异情况,分析其遗传进化特征。方法在流行季节采集发热病人咽拭子样本,经病毒分离培养及亚型鉴定后,用特异性引物扩增NA基因,测序并分析其遗传进化特征。结果 2009年7月至2011年3月,共检测监测样本1 898份,流感病毒阳性率为37.9%。期间经历了两次甲型H1N1流感病毒流行高峰。各时间段分离株间NA基因高度同源,序列相似性97.9%~100%,但2010/2011年流行株在进化树上分为两支,且与2009/2010年流行株遗传距离相对较远。进一步分析后发现,虽然耐药位点、酶活性位点及其附近氨基酸相对保守,但多个氨基酸变异发生于抗原决定簇上,且增加了NA蛋白茎部第42位糖基化位点。结论结果预示着酶抑制剂类药物对预防和治疗甲型H1N1流感病毒仍将有效,但在开发新疫苗时应该尽可能的避开已经发生漂变的抗原决定簇。 Objective To investigate the variations of the novel influenza A(H1N1) virus neuraminidase in strains isolated from Hangzhou,Zhejiang.Methods Throat swabs from influenza suspect patients were used for viral isolation.Influenza virus subtypes were identified by real-time RT-PCR.The strains of the novel influenza A(H1N1) virus were sequenced and phylogenetically analyzed.Results A total of 720(37.9%) strains of influenza virus were isolated from 1 898 throat swabs between July 2009 and March 2011.The homology of NA amino acid sequences ranged from 97.9% to 100%.The isolated strains of the novel influenza A(H1N1) virus were grouped into two clusters with a significant genetic distance by phylogenetic mapping with other strains.The variations of isolated strains may affect several known epitopes,but none of them was among drug binding sites.The presence of a novel putative glycosylation site was also confirmed at position 42 of the NA stalk.Conclusion The variations of H1N1 influenza NA gene did not affect neuraminidase inhibitors.However,epitope drift should be considered for vaccine development.
出处 《中国预防医学杂志》 CAS 2011年第10期830-834,共5页 Chinese Preventive Medicine
基金 杭州市卫生科技计划A类项目(项目编号:2011A055)
关键词 甲型H1N1流感病毒 神经氨酸酶 遗传进化 突变 Novel influenza A(H1N1) virus Neuraminidase Genetic evolution Mutation
  • 相关文献

参考文献18

  • 1Peiris JS, Pooh LL, Guan Y. Emergence of a novel swine-ori gin influenza A virus (S-OIV) H1N1 virus in humans [J]. J Clin Virol, 2009, 45 (3): 169- 173.
  • 2Oxford JS. Antivirals for the treatment and prevention of epi- demic and pandemic influenza [J]. Influenza Other Respi Viru- ses, 2007, 1 (1): 27- 34.
  • 3Deyde VM, Sheu TG, Trujillo AA, etal. Detection of molec- ular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing [J].Antimicrob Agents Chemother, 2010, 54 (3): 1102-1110.
  • 4Hoffmann E, Stech J, Guan Y, e tal. Universal primer set for the full length amplification of all influenza A viruses [J]. Arch Virol, 2001, 146 (12): 2275-2289.
  • 5Yang Z, PAML 4: phylogenetic analysis by maximum likeli- hood [J].Mol Biol Evol, 2007, 24 (8): 1586 -1591.
  • 6Crooks GE, Hon G, ChandoniaJM, et al. WebLogo: A se- quence logo generator [J].Genome Res, 2004, 14 (6): 1188- 1190.
  • 7Tamura K, Peterson D, Peterson N, et al. MEGAS: Molec- ular evolutionary genetics analysis using maximum likelihood evolutionary distance, and maximum parsimony methods [J] Mol Biol Evol, 2011. (In Press).
  • 8Gupta SK, Srivastava M, Akhoon BA, et al. Identification of immunogenic consensus T cell epitopes in globally distributed influenza A H1N1 neuraminidase [ J ]. Infect Genet Evol, 2011, 11 (2): 308-319.
  • 9Maurer Stroh S, Ma J, l.ee RT, et al. Mapping the sequence mutations of the 2009 H1N1 influenza A virus neuraminidase relative to drug and antibody binding sites [J].Biol Direct, 2009, 4: 18.
  • 10Mounier Jack S, Coker RJ. How prepared is Europe for pan- demic influenza? Analysis of national plans [ J ]. Lancet, 2006, 9520 (367): 1405 - 1411.

同被引文献43

  • 1Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A(H1N1) virus in humans[J].N EnglJ Med, 2009, 360(25):2605-2615.
  • 2Fanning TG, Reid AH, Taubenberger JK. Influenza A virus neuraminidase:regions of the protein potentially in- volved in virus-host interactions[J]. Virology, 2000, 276 (2) :417-423.
  • 3Maurer-Stroh S, Ma J, Lee RT, et al. Mapping the se- quence mutations of the 2009 H1N1 influenza A virus neuraminidase relative to drug and antibody binding sites [J]. Biol Direct, 2009, 4(1 ): 18.
  • 4Morlighem JE, Aoki S, Kishima M, et al. Mutation anal- ysis of 2009 pandemic influenza A (H1N1) viruses col- lected in Japan during the peak phase of the pandemic [J]. PLoS One, 2011, 6(4) :e18956.
  • 5Ferraris O, Lina B. Mutations of neuraminidase implicat-ed in neuraminidase inhibitors resistance[J].J Clin Vi- rol, 2008, 41(1):13-19.
  • 6Ahland K, Benson MD, Costello CE, et al. Genetic mi- eroheterogeneity of human transthyretin detected by IEF [J]. Eleetrophoresis, 2007, 28(12) :2053-2064.
  • 7Liu M, Chen H, Luo F, et al. Deletion of N-glycosyla- tion sites of hepatitis C virus envelope protein E1 en- hances specific cellular and humoral immune responses [J]. Vaccine, 2007, 25(36):6572-6580.
  • 8Abe Y, Takashita E, Sugawara K, et al. Effect of the addition of oligosaccharides on the biological activities and antigenicity of influenza A/H3N2 virus hemagglu- tinin[J]. J Virol, 2004, 78(18) :9605-9611.
  • 9Abed Y, Goyette N, Boivin G. Generation and charac- terization of recombinant influenza A (H1N1) viruses harboring anaantadine resistance mutations[J]. Antimi- crob Agents Chemother, 2005. 49(2) : 556-559.
  • 10Epperson S, Jhung M, Richards S, Quinlisk P, Ball I., Moll M, Boulton R, Haddy L, Biggerstaff M, Brammer L, Trock S, Burns E, Gomez T, Wong K K, Katz J, Lindstrom S, Klimov A, Bresee J S, Jernigan D B, Cox N, Finelli L. Human infections with influenza A (H3N2) variant virus in the United States, 2011-2012 [J]. ClinInfect Dis, 2013, 57(suppl 1): $4-Sll.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部